CAS: 473727-83-2

CXCR2 Antagonist IV, Sch527123, is a small molecule antagonist, which is a synthetic chemical compound with high specificity and affinity for the CXCR2 receptor. This receptor is primarily sourced from the leukocyte population, playing a significant role in the inflammatory response and immune cell trafficking. The primary mode of action of Sch527123 involves selectively binding to and blocking the CXCR2 receptor, thereby inhibiting the chemotactic activity mediated by CXCR2 ligands such as IL-8. This action disrupts the recruitment of neutrophils and other immune cells to sites of inflammation or injury, modulating the inflammatory response. In terms of applications, Sch527123 is a valuable tool in immunological research, particularly in studies investigating the pathways and mechanisms of inflammatory diseases. Its ability to modulate neutrophil activity makes it a subject of interest for potential therapeutic strategies in conditions characterized by excessive inflammation, such as chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, and other inflammatory disorders. As such, it is frequently employed in laboratory settings for in vitro and in vivo studies to further elucidate CXCR2-related pathways and to explore its potential as a therapeutic agent.

Navarixin

Applications Sch 527123 is a potent CXCR2 antagonist. It can potentially inhibits human colon cancer liver metastasis. References Varney, M. L., et al.: Cancer Lett 300, 180 (2011); Arshi, K., et al.: Front Immunol. 8, 464 (2017)

Navarixin (MK-7123)(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil